Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

INSMED Inc Director's Dealing 2024

Sep 16, 2024

30150_dirs_2024-09-16_41fce92b-cca5-4408-afd3-135a5c072974.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INSMED Inc (INSM)
CIK: 0001104506
Period of Report: 2024-09-12

Reporting Person: Flammer Martina M.D. (Chief Medical Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-09-12 Common Stock M 635 $34.03 Acquired 106769 Direct
2024-09-12 Common Stock S 635 $74.92 Disposed 106134 Direct
2024-09-13 Common Stock M 26969 $34.03 Acquired 133103 Direct
2024-09-13 Common Stock S 26969 $74.90 Disposed 106134 Direct
2024-09-16 Common Stock M 13436 $34.03 Acquired 119570 Direct
2024-09-16 Common Stock S 13436 $74.92 Disposed 106134 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-09-12 Stock Option (right to buy) $34.03 M 635 Disposed 2031-01-07 Common Stock (635) Direct
2024-09-13 Stock Option (right to buy) $34.03 M 26969 Disposed 2031-01-07 Common Stock (26969) Direct
2024-09-16 Stock Option (right to buy) $34.03 M 13436 Disposed 2031-01-07 Common Stock (13436) Direct

Footnotes

F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2: This is the weighted average sales price representing 635 shares sold at prices ranging from $74.90 to $74.93 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F3: This is the weighted average sales price representing 13,436 shares sold at prices ranging from $74.90 to $75.17 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F4: The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.